Eli Lilly weight loss drug site may not upend industry
Politics

The CEO of Eli Lilly expects a brand new weight reduction capsule to be accepted subsequent 12 months

By UMass Mag

David Ricks, CEO, Eli Lilly

Scott Mlyn | CNBC

Eli Lilly expects its experimental weight-loss pill to be approved as early as early next year, CEO David Ricks told Bloomberg TV on Monday.

The company is expected to release key late-stage trial data for the drug orforglipron by the middle of this year.

Eli Lilly is pushing to bring the pill to market because it competes with it Novo Nordisk and smaller competitors are capturing much of the booming weight-loss drug market. Eli Lilly's Zepbound and Novo Nordisk's Wegovy dominate the market, but drugmakers and their competitors are working to develop improved versions of the drugs.

Tablets would be more convenient for patients than current injectable forms. They would also be easier to produce, as Eli Lilly and Novo Nordisk are struggling to produce enough drugs to keep up with rising demand.

Eli Lilly said orforglipron helped patients in a mid-stage trial lose up to 14.7% of their weight, compared with 2.3% for people taking a placebo.

Shares of Eli Lilly traded about 2% lower on Monday.

Subscribe to CNBC on YouTube.

UMass Mag 10127 posts 0 comments

Jim Faile has done it all in his 27 year as an Author, Editor, Writer, Copywriter, Blogger, and Mentor. You name a newsroom beat and Jim has covered it with the best of them. He also loves his dogs, traveling, Rays baseball, and dreaming up his next writing project.

You might also like More from author

Comments are closed.